Blog | Life Sciences

A centralized platform for global content development can empower patient engagement teams to deliver personalized care to a broad scope of patient populations.

A unitary patent is intended to simplify the European patent system in up to 25 EU Member States. Learn how unitary patents will affect life sciences companies.

Centralizing global content for medical affairs teams provides many benefits, including a more streamlined process. Learn more about global content solutions.

The life sciences industry has always generated enormous amounts of data. In a digital age, data proliferation in life sciences is more vigorous than ever, to the extent that data may be as essential to a company’s value proposition as its pipeline, products, or research and development (R&D).

It is only in more recent years, though, with the emergence of artificial intelligence (AI) and machine learning (ML), that the industry has started to leverage the full potential of its data reserves in the patient’s journey, R&D, manufacturing, and even marketing. However, since a lot of the produced data is unstructured, there is a need for annotation and augmentation services to ensure this data is put to best use.

The Quality Review of Documents (QRD V9) update came into effect on January 28, 2022. The new version consists of a set of guidelines established by the European Medicines Agency (EMA) outlining the responsibilities and duties of those who ensure the quality of veterinary medicines. The update to V9.0 includes several key changes aimed at improving the overall quality of veterinary care and prioritizing animal welfare.

Life sciences organizations face challenges with recruiting for clinical trials using social media due to regulations. Learn four ways to overcome challenges.

International Women's Day is celebrated annually on March 8 to recognize the social, economic, cultural, and political achievements of women worldwide.

Now that the EU Clinical Trial Regulation is in effect, what are the impacts of the second transition period (2023–2025) on IMP labeling activities? Learn more.

Notifying Bodies have been vocal on the need for clinical studies to be more patient-centric and diverse. Technology can help capture the patient voice.

A central technology platform for global regulatory submissions can help pharma companies decrease timelines, ensure consistency, and maximize ROI. Learn more.

EU Clinical Trials Regulation (CTR) is mandatory for any initial submission of clinical trials with investigational medicinal products. Are you ready?

While electronic labels for investigational medicinal products aren't required by the EU CTR, sponsors should be prepared given their numerous benefits.